HIV was identified as the cause of AIDS.
The first HIV vaccine clinical trial opened at the National Institutes of Health (NIH) Clinical Center in Bethesda, Maryland. This Phase I trial enrolled 138 healthy, uninfected volunteers. The gp160 subunit vaccine showed no serious adverse effects.
The NIAID AIDS Vaccine Evaluation Group (AVEG), the first U.S. cooperative HIV vaccine clinical trials group, began enrolling volunteers in its first trial.
NIAID launched the first Phase II HIV vaccine clinical trial. This trial included uninfected volunteers with a history of high-risk behavior -- injection drug use, multiple sex partners, or sexually transmitted infections. Participants were counseled repeatedly to avoid any behaviors that put them at risk of HIV infection.
VaxGen candidate failed in Phase III trials.
NIAID halted the Phase II Step and Phambili studies due to safety concerns.
HVTN 505 expanded to include protection from HIV as primary endpoint.
Additional analyses of samples from RV144 provide insight about what type of immune response may be needed for an effective vaccine.
HVTN 505 immunizations stopped due to lack of efficacy.
Last Updated May 21, 2013
Last Reviewed July 31, 2012